论文部分内容阅读
目的探讨分析阿奇霉素治疗社区获得性肺炎(CAP)的临床疗效及安全性。方法 140例CAP患者随机分为对照组和研究组,各70例。对照组采用常规治疗,研究组在对照组基础上给予阿奇霉素进行治疗,比较两组患者临床疗效和不良反应。结果研究组总有效率为92.86%明显高于对照组的80.00%(P<0.05)。研究组不良反应总发生率(7.14%)明显低于对照组(20.00%)(P<0.05)。结论临床治疗CAP可采用阿奇霉素进行治疗,此治疗方式可提高患者临床治疗疗效,且安全可靠,对改善患者生活质量有明显作用。
Objective To investigate the clinical efficacy and safety of azithromycin in the treatment of community-acquired pneumonia (CAP). Methods 140 patients with CAP were randomly divided into control group and study group, 70 cases in each. The control group was treated by conventional therapy. The study group was treated with azithromycin on the basis of the control group, and the clinical efficacy and adverse reactions were compared between the two groups. Results The total effective rate of the study group was 92.86%, which was significantly higher than that of the control group (80.00%, P <0.05). The total incidence of adverse reactions in the study group (7.14%) was significantly lower than that in the control group (20.00%) (P <0.05). Conclusion The clinical treatment of CAP can be treated with azithromycin, this treatment can improve the clinical efficacy of patients, and safe and reliable, to improve the quality of life of patients has a significant effect.